Ringlike Late Gadolinium Enhancement Provides Incremental Prognostic Value in Non-classical Arrhythmogenic Cardiomyopathy

Overview

Journal J Cardiovasc Magn Reson

Publisher Elsevier

Specialties Cardiology & Vascular Diseases
Radiology

Date 2023 Nov 30

PMID 38031154

Authors

Yuelong Yang

Xiaoyu Wei

Guanyu Lu

Jiajun Xie

Zekun Tan

Zhicheng Du

Weitao Ye

Huanwen Xu

Xiaodan Li

Entao Liu

Qianhuan Zhang

Yang Liu

Jinglei Li

Hui Liu

Affiliations

Soon will be listed here.

Abstract

Background: The 2019 arrhythmogenic right ventricular cardiomyopathy (ARVC) risk model has proved insufficient in the capability of predicting ventricular arrhythmia (VA) risk in non-classical arrhythmogenic cardiomyopathy (ACM). Furthermore, the prognostic value of ringlike late gadolinium enhancement (LGE) of the left ventricle in non-classical ACM remains unknown. We aimed to assess the incremental value of ringlike LGE over the 2019 ARVC risk model in predicting sustained VA in patients with non-classical ACM.

Methods: In this retrospective study, consecutive patients with non-classical ACM who underwent CMR from January 2011 to January 2022 were included. The pattern of LGE was categorized as no, non-ringlike, and ringlike LGE. The primary outcome was defined as the occurrence of sustained VA. Univariable and multivariable Cox regression analysis was used to evaluate the impact of LGE patterns on sustained VA and area under curve (AUC) was calculated for the incremental value of ringlike LGE.

Results: A total of 73 patients were collected in the final cohort (mean age, 39.3 ± 14.4 years, 51 male), of whom 10 (13.7%) had no LGE, 33 (45.2%) had non-ringlike LGE, and 30 (41.1%) had ringlike LGE. There was no statistically significant difference in the 5-year risk score among the three groups (P = 0.190). During a median follow-up of 34 (13-56) months, 34 (46.6%) patients experienced sustained VA, including 1 (10.0%), 13 (39.4%) and 20 (66.7%) of patients with no, non-ringlike and ringlike LGE, respectively. After multivariable adjustment, ringlike LGE remained independently associated with the presence of sustained VA (adjusted hazard ratio: 6.91, 95% confidence intervals: 1.89-54.60; P = 0.036). Adding ringlike LGE to the 2019 ARVC risk model showed significantly incremental prognostic value for sustained VA (AUC: 0.80 vs. 0.67; P = 0.024).

Conclusion: Ringlike LGE provides independent and incremental prognostic value over the 2019 ARVC risk model in patients with non-classical ACM.

Citing Articles

Artificial Intelligence Advancements in Cardiomyopathies: Implications for Diagnosis and Management of Arrhythmogenic Cardiomyopathy.

Salavati A, van der Wilt C, Calore M, van Es R, Rampazzo A, van der Harst P Curr Heart Fail Rep. 2024; 22(1):5.

PMID: 39661213 DOI: 10.1007/s11897-024-00688-4.

References

Bondarenko O, Beek A, Hofman M, Kuhl H, Twisk J, van Dockum W . Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson. 2005; 7(2):481-5. DOI: 10.1081/jcmr-200053623. View

Te Riele A, Bhonsale A, Burt J, Zimmerman S, Tandri H . Genotype-specific pattern of LV involvement in ARVD/C. JACC Cardiovasc Imaging. 2012; 5(8):849-51. DOI: 10.1016/j.jcmg.2012.06.004. View

Zghaib T, Te Riele A, James C, Rastegar N, Murray B, Tichnell C . Left ventricular fibro-fatty replacement in arrhythmogenic right ventricular dysplasia/cardiomyopathy: prevalence, patterns, and association with arrhythmias. J Cardiovasc Magn Reson. 2021; 23(1):58. PMC: 8135158. DOI: 10.1186/s12968-020-00702-3. View

Disertori M, Rigoni M, Pace N, Casolo G, Mase M, Gonzini L . Myocardial Fibrosis Assessment by LGE Is a Powerful Predictor of Ventricular Tachyarrhythmias in Ischemic and Nonischemic LV Dysfunction: A Meta-Analysis. JACC Cardiovasc Imaging. 2016; 9(9):1046-1055. DOI: 10.1016/j.jcmg.2016.01.033. View

Hulot J, Jouven X, Empana J, Frank R, Fontaine G . Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004; 110(14):1879-84. DOI: 10.1161/01.CIR.0000143375.93288.82. View

Bosman L, Sammani A, James C, Cadrin-Tourigny J, Calkins H, van Tintelen J . Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis. Heart Rhythm. 2018; 15(7):1097-1107. DOI: 10.1016/j.hrthm.2018.01.031. View

Augusto J, Eiros R, Nakou E, Moura-Ferreira S, Treibel T, Captur G . Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. Eur Heart J Cardiovasc Imaging. 2019; 21(3):326-336. DOI: 10.1093/ehjci/jez188. View

Chen W, Qian W, Zhang X, Li D, Qian Z, Xu H . Ring-like late gadolinium enhancement for predicting ventricular tachyarrhythmias in non-ischaemic dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2021; 22(10):1130-1138. DOI: 10.1093/ehjci/jeab117. View

Austin K, Trembley M, Chandler S, Sanders S, Saffitz J, Abrams D . Molecular mechanisms of arrhythmogenic cardiomyopathy. Nat Rev Cardiol. 2019; 16(9):519-537. PMC: 6871180. DOI: 10.1038/s41569-019-0200-7. View

10.

Aquaro G, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N . Prognostic Value of Magnetic Resonance Phenotype in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. J Am Coll Cardiol. 2020; 75(22):2753-2765. DOI: 10.1016/j.jacc.2020.04.023. View

11.

Pinamonti B, Dragos A, Pyxaras S, Merlo M, Pivetta A, Barbati G . Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. Eur Heart J. 2011; 32(9):1105-13. DOI: 10.1093/eurheartj/ehr040. View

12.

Ota S, Orii M, Nishiguchi T, Yokoyama M, Matsushita R, Takemoto K . Implications of multiple late gadolinium enhancement lesions on the frequency of left ventricular reverse remodeling and prognosis in patients with non-ischemic cardiomyopathy. J Cardiovasc Magn Reson. 2021; 23(1):32. PMC: 7992777. DOI: 10.1186/s12968-021-00734-3. View

13.

Bosman L, Te Riele A . Arrhythmogenic right ventricular cardiomyopathy: a focused update on diagnosis and risk stratification. Heart. 2021; 108(2):90-97. DOI: 10.1136/heartjnl-2021-319113. View

14.

Te Riele A, Tandri H, Bluemke D . Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update. J Cardiovasc Magn Reson. 2014; 16:50. PMC: 4222825. DOI: 10.1186/s12968-014-0050-8. View

15.

Towbin J, McKenna W, Abrams D, Ackerman M, Calkins H, Darrieux F . 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019; 16(11):e301-e372. DOI: 10.1016/j.hrthm.2019.05.007. View

16.

Halliday B, Baksi A, Gulati A, Ali A, Newsome S, Izgi C . Outcome in Dilated Cardiomyopathy Related to the Extent, Location, and Pattern of Late Gadolinium Enhancement. JACC Cardiovasc Imaging. 2018; 12(8 Pt 2):1645-1655. PMC: 6682609. DOI: 10.1016/j.jcmg.2018.07.015. View

17.

Marcus F, McKenna W, Sherrill D, Basso C, Bauce B, Bluemke D . Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010; 121(13):1533-41. PMC: 2860804. DOI: 10.1161/CIRCULATIONAHA.108.840827. View

18.

Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, De Lazzari M . Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. Int J Cardiol. 2020; 319:106-114. DOI: 10.1016/j.ijcard.2020.06.005. View

19.

Liu J, Zhao S, Yu S, Wu G, Wang D, Liu L . Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy. Radiology. 2021; 302(2):298-306. DOI: 10.1148/radiol.2021210914. View

20.

Al-Khatib S, Stevenson W, Ackerman M, Bryant W, Callans D, Curtis A . 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and.... Heart Rhythm. 2017; 15(10):e73-e189. DOI: 10.1016/j.hrthm.2017.10.036. View